Gene Therapy may be the Way Forward to Treat Genetic Blindness

Study shows first-of-its-kind gene therapy can restore vision to people with an inherited retinal disorder.

New gene therapy allowed patients who had lost their sight to an inherited retinal disease to see well enough to navigate a maze, according to research presented today at AAO 2017, the 121st Annual Meeting of the American Academy of Ophthalmology.

Patients in the study had a condition called Leber congenital amaurosis (LCA), which begins in infancy and progresses slowly, eventually causing complete blindness. This new, first-of-its-kind gene therapy is currently under review by the U.S. Food and Drug Administration for potential approval this year. There are currently no treatments available for inherited retinal diseases.

Study Identifies Novel Pathway to Fight Retinal Disease, Cancer
Researchers at Cincinnati Children's Hospital Medical Center have identified a new molecular pathway that is designed to suppress blood vessel pattering in the developing retina.

‘Voretigene neparvovec, gene therapy, restored light sensitivity in patients with inherited blindness and enabled them to navigate in low light.’

Ophthalmologist Stephen R. Russell, M.D., of the University of Iowa, is one of the lead researchers for this pioneering treatment. Data from the first randomized, controlled, phase 3 study showed that 27 of 29 treated patients (93 percent) experienced meaningful improvements in their vision, enough that they could navigate a maze in low to moderate light. They also showed improvement in light sensitivity and peripheral vision, which are two visual deficits these patients experience.

Approval could open the door for other gene therapies that could eventually treat the more than 225 genetic mutations known to cause blindness. It could be applied to retinitis pigmentosa, another inherited retinal disease caused by a defective gene. Or in the future, gene therapy could possibly provide key proteins needed to restore vision in more common diseases such as age-related macular degeneration.

LCA is rare, affecting about 1 in 80,000 individuals. It can be caused by one or more of 19 different genes. The treatment, called voretigene neparvovec (Luxturna, Spark Therapeutics), involves a genetically modified version of a harmless virus. The virus is modified to carry a healthy version of the gene into the retina. Doctors inject billions of modified viruses into both of a patient’s eyes.

Medical and Technological Advances Helping Patients With Retinal Diseases Avoid Life-Long Blindness
New advances, both in the field of medicine and technology, are helping a growing number of people with retinal diseases rediscover their vision.

Treatment doesn’t restore normal vision. It does, however, allow patients to see shapes and light, allowing them to get around without a cane or a guide dog. It is unclear how long the treatment will last, but so far, most patients have maintained their vision for two years.

More than 200 patients with LCA have participated in gene therapy trials since 2007. However, no gene therapy has gotten this close to FDA approval for retinal disease or any other eye disease. In October, an advisory committee to the FDA unanimously endorsed the treatment. The FDA isn’t obligated to follow the recommendations of its advisory committees, but it usually does. The agency is expected to make its decision no later than January 2018.

New Structure in Dogs' Eye Linked to Blinding Retinal Diseases Identified by Penn Team
A tiny area in the center of the retina called the fovea is critically important to viewing fine details in humans.

Source-Eurekalert

Zika Virus Infection Linked to Severe Damage of the Retina in Infants
Congenital Zika syndrome has been associated with retinal abnormalities in the newborn, suggests a new study.